Comparison between BSS 2006 and 2009 data indicates a relative increase selleck products in condom use at last sexual encounter with commercial male partners with time. For example, in Andhra Pradesh, the proportion rose from 86% in 2006

to 100% in 2009, and in Maharashtra it increased from 63% to 91%. Similarly, condom use during the last time they engaged in sex with a noncommercial partner also increased between 2006 and 2009. A higher proportion of respondents (group I) in 2009 (89%–97%) than in 2006 (67%–88%) reported using a condom at last sexual encounter with a noncommercial partner. The mean number of commercial sexual partners in group I states was the highest in the state of Karnataka (25 partners in 1 month) and was lowest in Maharashtra (four partners in 1 month) as per BSS 2009. The mean number of commercial partners in group III states was three to six and for group IV states (Uttar Pradesh) was eleven, as observed in BSS 2006. The proportion of MSM having sex with women at least once in the past 6 months is >50% in some of the states (being 64% and 52% in group I states of Andhra Pradesh and Karnataka respectively, and 58% and 56% in the group III states of Gujarat and Puducherry, respectively,

as per HSS 2008–09). Manipur from group II states reported the lowest (5% as per BSS 2009), while Uttar Pradesh from group IV states was the highest (69% as per BSS 2009). Moreover, the comparison between BSS 2006 and HSS 2008–09 suggests an increased percentage of MSM having sex with female partners. Current national response to the MSM epidemic Table 3 provides a description of data related to program coverage and its activities, compiled from multiple sources. Of the total estimated denominator for MSM in India, the national program through targeted intervention projects has covered 69% (2010–11) of MSM and transgenders. Coverage varied

between 38% and 100% within group I states, between 76% and 100% within group II states, between 32% and 100% in group III states, and between 0% and 100% in group IV states. The estimated coverage has increased over time Carfilzomib as the number of targeted interventions has increased from 31 in 2004–05 to 155 in 2010–11. For example, the estimated coverage of MSM increased from 37% in 2004–05 to 64% in 2010–11 in the four southern high prevalence states (group I). Similarly, the estimated proportion of condoms distributed to MSM rose from 2009–10 to 2010–11, ranging from 13% to 94% in group I states, 17%–46% in group II states, 16%–100% in group III states, and 0%–56% in group IV states.